GLPwatch
Papers (9189)
Page 126 of 154, ranked by citation count.
- Artificial intelligence and natural language processing of patient narratives to evaluate semaglutide for weight loss.
- An analysis of national news coverage of semaglutide for weight loss.
- Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database.
- Exenatide improves cisplatin induced ovarian damage through NLRP3, Nrf-2, and TLR4 pathways.
- [Diabetic ketoacidosis after switching insulin for exenatide].
- Treatment of obesity in spinal cord injury with tirzepatide: a case report.
- Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.
- Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin.
- Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.
- Repurposing liraglutide to the management of DSS-induced colitis: a potential for promoting autophagy.
- Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.
- Recombination and functional studies of a dual-action peptide for diabetes.
- Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application.
- Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats.
- Liraglutide attenuates aluminum chloride-induced Alzheimer's disease in rats by modulating the oxLDL/LPA/LPAR1 pathway.
- Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.
- Exploring novel protective role of semaglutide in 5-fluorouracil-induced hepatotoxicity: Insights into phosphorylated CREB, PINK1/Parkin-mediated mitophagy, and NF-κB/NLRP3 pathways.
- Microbial expression of Exendin-4 analog and its efficacy in mice model.
- GLP-1 and GIP Changes after Sleeve Gastrectomy and Weight Regain in Adolescents. Do we need a Boost?
- Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.
- Letter to Liu et al.'s "Efficacy of Exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome".
- Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial.
- A Retrospective Analysis of Liraglutide (GLP-1 Agonist) Use in a Chinchilla (<i>Chinchilla lanigera</i>) Model of Auditory Blast Injury.
- Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide.
- A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes.
- Exploring the nephroprotective effects of combined finerenone and exenatide therapy in diabetic nephropathy.
- Effects of semaglutide in patients with chronic ankle instability: evidence from a prospective cohort.
- Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data.
- Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.
- A microfluidic in vitro method predicting the fate of peptide drugs after subcutaneous administration.
- The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care.
- Uncovering the potential molecular mechanism of liraglutide to alleviate the effects of high glucose on myoblasts based on high-throughput transcriptome sequencing technique.
- RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.
- Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.
- Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.
- Oral semaglutide for the treatment of obesity: a retrospective real-world study.
- ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine.
- Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Patients with Polycystic Ovary Syndrome and Obesity.
- Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.
- Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence.
- Prospective, Matched Case-Control Study of Endoscopic Sleeve Gastroplasty and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease at One Year.
- Navigating Glucagon-Like Peptide Receptor Agonist Reinitiation Amid Access Barriers: An Adverse Drug Event Case Report.
- After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
- M14 substitutions in exanatide modulate alpha-synuclein aggregation.
- Response to "Liraglutide effect on epicardial fat: Missing the forest for the trees".
- Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information-Based Mapping Exercises Across the 42 Integrated Care Boards of England.
- Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers.
- Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.
- Slimming cardiac adipose tissue with liraglutide: pericardial is not epicardial fat (the LIRAFLAME substudy).
- Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide.
- Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies.
- Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Randomized Clinical Trial.
- Recurrent weight gain after sleeve gastrectomy: conversion to Roux-en-Y gastric bypass versus novel GLP-1 s.
- Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?
- Some Risks of Gastrointestinal Adverse Events Associated With Glucagon-Like PEPTIDE-1 Receptor Agonists Are Likely Explained by BMI.
- Detection of adverse drug reactions among ordinary users of liraglutide on the occasion of drug dispensing in the community pharmacy setting.
- Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study.
- Insulin degludec + liraglutide: a complementary combination.
- Is there a role for the incretin system in blood pressure regulation?
- The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review.